These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29172528)

  • 41. Monofunctional BODIPY-Appended Imidazoplatin for Cellular Imaging and Mitochondria-Targeted Photocytotoxicity.
    Raza MK; Gautam S; Garai A; Mitra K; Kondaiah P; Chakravarty AR
    Inorg Chem; 2017 Sep; 56(18):11019-11029. PubMed ID: 28846407
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as σ receptor ligands with potential neuroprotective effects.
    Banister SD; Manoli M; Barron ML; Werry EL; Kassiou M
    Bioorg Med Chem; 2013 Oct; 21(19):6038-52. PubMed ID: 23981939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 1-Cyclohexyl-4-(4-arylcyclohexyl)piperazines: Mixed σ and human Δ(8)-Δ(7) sterol isomerase ligands with antiproliferative and P-glycoprotein inhibitory activity.
    Abate C; Niso M; Contino M; Colabufo NA; Ferorelli S; Perrone R; Berardi F
    ChemMedChem; 2011 Jan; 6(1):73-80. PubMed ID: 21069657
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Licofelone-nitric oxide donors as anticancer agents.
    Liu W; Zhou J; Liu Y; Liu H; Bensdorf K; Guo C; Gust R
    Arch Pharm (Weinheim); 2011 Aug; 344(8):487-93. PubMed ID: 21681808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Controlled Delivery of Nitric Oxide for Cancer Therapy.
    Alimoradi H; Greish K; Gamble AB; Giles GI
    Pharm Nanotechnol; 2019; 7(4):279-303. PubMed ID: 31595847
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy.
    Ren SZ; Wang ZC; Zhu D; Zhu XH; Shen FQ; Wu SY; Chen JJ; Xu C; Zhu HL
    Eur J Med Chem; 2018 Sep; 157():909-924. PubMed ID: 30149323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New analogs of SYA013 as sigma-2 ligands with anticancer activity.
    Asong G; Zhu XY; Bricker B; Andey T; Amissah F; Lamango N; Ablordeppey SY
    Bioorg Med Chem; 2019 Jun; 27(12):2629-2636. PubMed ID: 30987780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Light-Tunable Generation of Singlet Oxygen and Nitric Oxide with a Bichromophoric Molecular Hybrid: a Bimodal Approach to Killing Cancer Cells.
    Fraix A; Blangetti M; Guglielmo S; Lazzarato L; Marino N; Cardile V; Graziano AC; Manet I; Fruttero R; Gasco A; Sortino S
    ChemMedChem; 2016 Jun; 11(12):1371-9. PubMed ID: 26537319
    [TBL] [Abstract][Full Text] [Related]  

  • 49. σ
    Abatematteo FS; Niso M; Lacivita E; Abate C
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34205334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.
    Huang Z; Fu J; Zhang Y
    J Med Chem; 2017 Sep; 60(18):7617-7635. PubMed ID: 28505442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor cell specific and lysosome-targeted delivery of nitric oxide for enhanced photodynamic therapy triggered by 808 nm near-infrared light.
    Xiang HJ; Deng Q; An L; Guo M; Yang SP; Liu JG
    Chem Commun (Camb); 2016 Jan; 52(1):148-51. PubMed ID: 26503188
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct Photocontrol of Peptidomimetics: An Alternative to Oxygen-Dependent Photodynamic Cancer Therapy.
    Babii O; Afonin S; Garmanchuk LV; Nikulina VV; Nikolaienko TV; Storozhuk OV; Shelest DV; Dasyukevich OI; Ostapchenko LI; Iurchenko V; Zozulya S; Ulrich AS; Komarov IV
    Angew Chem Int Ed Engl; 2016 Apr; 55(18):5493-6. PubMed ID: 27028784
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands.
    Sun YT; Wang GF; Yang YQ; Jin F; Wang Y; Xie XY; Mach RH; Huang YS
    Eur J Med Chem; 2018 Mar; 147():227-237. PubMed ID: 29438891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design, synthesis and cytotoxic evaluation of nitric oxide-releasing derivatives of isosteviol.
    Liu Y; Wang T; Ling Y; Bao N; Shi W; Chen L; Sun J
    Chem Biol Drug Des; 2017 Sep; 90(3):473-477. PubMed ID: 28122177
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nitroreductase-activated nitric oxide (NO) prodrugs.
    Sharma K; Sengupta K; Chakrapani H
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5964-7. PubMed ID: 24050886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel α-ketoamide based diazeniumdiolates as hydrogen peroxide responsive nitric oxide donors with anti-lung cancer activity.
    Fu J; Han J; Meng T; Hu J; Yin J
    Chem Commun (Camb); 2019 Oct; 55(86):12904-12907. PubMed ID: 31584577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
    Chattopadhyay M; Kodela R; Olson KR; Kashfi K
    Biochem Biophys Res Commun; 2012 Mar; 419(3):523-8. PubMed ID: 22366248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Editorial: Throwing Light on Recent Advances on Metallodrugs: From Deemed Poisons to a Striking Hope for the Future.
    Nardon C; Fregona D
    Curr Med Chem; 2018 Feb; 25(4):434-436. PubMed ID: 29494325
    [No Abstract]   [Full Text] [Related]  

  • 59. Design and Investigation of a [
    Yang D; Comeau A; Bowen WD; Mach RH; Ross BD; Hong H; Van Dort ME
    Mol Pharm; 2017 Mar; 14(3):770-780. PubMed ID: 28135101
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of sigma-1 (σ1) receptor fluorescent ligands as versatile tools to study σ1 receptors.
    Abate C; Riganti C; Pati ML; Ghigo D; Berardi F; Mavlyutov T; Guo LW; Ruoho A
    Eur J Med Chem; 2016 Jan; 108():577-585. PubMed ID: 26717207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.